TNYA

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

Wall Street analysts forecast TNYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNYA is 11.33 USD with a low forecast of 3.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tenaya Therapeutics Inc revenue for the last quarter amounts to -20.94M USD, decreased -21.62 % YoY.

Tenaya Therapeutics Inc. EPS for the last quarter amounts to -15625000.00 USD, decreased -21.95 % YoY.

Tenaya Therapeutics Inc (TNYA) has 97 emplpoyees as of December 16 2025.

Today TNYA has the market capitalization of 172.56M USD.